1 September 2024

VivaGel® Coated Condom: Licence Agreement for Japan with Okamoto

Melbourne, Australia;  Starpharma Holdings Limited (ASX:SPL, OTCQX:SPHRY) today announced that it has signed a licence agreement with Okamoto Industries Inc  (TSE: JP3192800005) in relation to the VivaGel®-coated condom for the Japanese market.  Okamoto is the market leader for condoms sold in Japan, the world’s second largest condom market.

 

Under the terms of this agreement Okamoto secures marketing rights to the VivaGel®-coated condom in Japan.  Starpharma will receive royalty and milestone payments and Okamoto will undertake registration and launch of the product in Japan. The coated condoms marketed by Okamoto will carry the VivaGel® brand.

 

“We are particularly pleased to be working with Okamoto, which has both the market-leading position and the regulatory and commercial strengths to maximise value creation for the VivaGel®-coated condom in Japan,” said Dr Jackie Fairley, Starpharma’s CEO.

 

“Okamoto is the ideal partner for the Japanese market with an outstanding product portfolio and heritage in the successful commercialization of new products.  This is an exciting new market for the VivaGel®-coated condom.”

 

Okamoto is Japan’s leading marketer of condoms with approximately 60% share of the Japanese condom market[i]. The Japanese condom market has been estimated to be in the order of US $500 million in 2009i.  Okamoto, based in Tokyo, has total revenues of more than US $760 million and over 1,700 employees.  In addition to its dominant position in the Japanese condom market, Okamoto also holds strong market positions in several other Asian markets, including Korea, Taiwan, Malaysia, Singapore and China.


 Mr Yumoto, a Director of Okamoto commented: “The VivaGel®-coated condom is an excellent technological advance and we look forward to progressing to market launch with this exciting new product.”

 

In addition to the VivaGel®-coated condom, Starpharma is separately developing VivaGel® as an applicator-delivered vaginal product for use by women to protect themselves from HIV and HSV-2 (genital herpes) and for the treatment and prevention of bacterial vaginosis.

 

[i] Market Data Bank (MDB) Report issued February 2009, Condoms: A Global Strategic Business Report (2005, 2008) and Industry Data

 

Download ASX Announcement: Licence Agreement for Japan with Market Leader Okamoto (pdf file, 188kb)

 


About Okamoto Industries, Inc.

Okamoto Industries Inc (TSE:JP3192800005) headquartered in Tokyo, Japan and established in 1934, has earned an international reputation as a leading manufacturer of quality rubber and plastic products. Okamoto’s flexibility has enabled adaptation of the product lines to the needs and trends of the market and to pioneer new products through research and development. Only products achieving the highest standards of quality will display the Okamoto name. Okamoto are concerned about people and the environment in the realm of rubber and plastic products. Pursuing this goal, Okamoto continue manufacturing products with originality and the highest quality standards.


This contains certain forward-looking statements.

This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.